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Background: In 2015, around 17.9 million people died from cardiovascular disease 
worldwide, with myocardial infarction being the most common manifestation. Contemporary 
research suggests that omega-3 (n-3) polyunsaturated fatty acid (PUFA) interventions have 
less useful cardiovascular outcomes than previously thought. This study aims to examine the 
association between n-3 PUFA intake frequency and the risk of fatal myocardial infarction 
(FMI) by using food frequency questionnaires and adjust for confounding factors.  
Method: The Norwegian Women and Cancer (NOWAC) study is a population-based cohort 
that utilizes self-reported data obtained from already existing population registries and 
questionnaires, in which four out of a total of eight pages contained questions regarding 
dietary habits. Data from 101,316 eligible Norwegian women (mean age: 52.24 years, range: 
41–76 years) were analyzed. A total of 22,395 subjects were excluded according to 
predefined criteria, such as prevalent disease. Data on FMI were obtained from the 
Norwegian Cause of Death Registry. The participants were divided into three n-3 PUFA 
intake frequency groups: never, intermittent, and daily. The relationship between n-3 PUFA 
supplement intake and FMI was assessed using a Cox proportional hazards model.  
A stratified model was constructed according to the median intake of fatty fish (11 g/day) to 
assess the separate effect within groups of high and low fatty fish intake. 
Results: Over an average of 18.41 years of follow-up, 256 cases of FMI were reported. The 
crude incidence rate was found to be 17 per 100,000, and a nonsignificant inverse association 
was observed. The estimates for intermittent and daily intake (compared to never) according 
to the multivariate-adjusted model were respectively hazard ratios (HRs) of 0.95 (95% 
confidence interval [CI]: 0.72-1.26) and 0.85 (95% CI: 0.60-1.20). The estimates of the 
association between n-3 PUFA supplement intake and FMI among those with low intake of 
fatty fish, according to the multivariate-adjusted model, were an HR of 0.65 (95% CI: 0.39–
1.09). Hence, the multivariate-adjusted model was statistically insignificant. 
Conclusions: More frequent intake of n-3 PUFA supplements is not associated with a lower 
risk of FMI among women in the NOWAC study. 
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Cardiovascular disease (CVD) is a group of interrelated diseases that include coronary heart 
disease (CHD), hypertension, atherosclerosis, ischemic heart disease, heart failure, and 
peripheral vascular disease (1). For decades, the mortality rates associated with CVD have 
been of concern (2). In 2015, around 17.9 million people died from CVD worldwide. 
Although cancer is currently the most common cause of death, CVD remains the main cause 
of death among people aged above 70 in Norway (3). Generally, CVD is a noncommunicable 
disease that is considered to be highly preventable through lifestyle choices, such as smoking 
cessation, increased physical activity, and healthy dietary habits (2, 4). Myocardial infarction 
(MI) is the most common manifestation of CVD responsible for deaths (1). According to the 
Norwegian Myocardial Infarction Registry, 12,393 cases of MI have been reported among 
11,772 individuals in 2018, some of whom had multiple events of MI (5).  
 
1.1 Myocardial infarction 
MI is defined by the necrosis of myocardial cells as a result of oxygen shortage (ischemia), 
which can cause tissue damage and cell dysfunction (6). Atherosclerosis, which is the 
narrowing and loss of elasticity of the blood vessel wall as a result of plaque accumulation, is 
considered the “silent” precursor to MI because it is often asymptomatic until the first cardiac 
event (1). In general, MI is most often caused by obstruction due to atherosclerosis and 
plaque. Clinically, it may manifest either as a minor coronary event or as a life-threatening 
condition or even sudden death. People with a history of MI are predisposed to repeated 
events. Age, male sex, loss of estrogen (due to natural or surgical menopause), family history, 
and genetic susceptibility are some of the important nonmodifiable risk factors of MI (1, 7, 8). 
Hyperlipidemia, which is the genetic predisposition to a disadvantageous lipid profile, 
exhibits several known types, such as familial hypercholesterolemia, polygenic familial 
hypercholesterolemia, familial combined hyperlipidemia, and familial dysbetalipoproteinemia 
(1). The most important modifiable lifestyle risk factors of MI are smoking, psychosocial 
factors, diabetes, obesity and overweight, hypertension, metabolic syndrome, and physical 




protective effects (8). Triglycerides are the most abundant lipid consumed by humans, and 
serum levels have been associated with the risk of CHD (9-12). A study also showed that 4 g 
of n-3 PUFA per day decreased plasma triglyceride concentrations by 25-30% (10). Also, 
saturated fatty acids (SFAs) and cholesterol are associated with CVD (13). Higher intake of 
SFAs is associated with an increased level of low-density lipoprotein (LDL) cholesterol. 
Lipoproteins are generally important in the transport of fats as they are insoluble in water. In 
contrast to LDL cholesterol, high-density lipoprotein (HDL) cholesterol is considered the 
healthy type of cholesterol. Replacing SFAs with polyunsaturated fatty acids (PUFAs) can 
reduce the risk of CVD by decreasing the LDL/HDL ratio. CVD has also been associated 
with higher production of proinflammatory factors, and plasma levels of omega-3 (n-3) 
PUFAs have been inversely associated with inflammatory markers, such as C-reactive 
protein, interleukin-6, fibrinogen, and homocysteine (1). 
 
1.2 Polyunsaturated fatty acids 
Fatty acids are macronutrients that vary in terms of their hydrocarbon chain length as well as 
the number and position of bonds (12). Identification of a fatty acid depends on the position 
of the carbon in the double bond relative to the methyl group end of the chain. The term “n” 
indicates the distance from the methyl group end to the first carbon double bond along the 
chain. Monounsaturated fatty acids (MFAs) should be at least 12 carbon atoms in length, 
most commonly with double bonds at n-7 or n-9. Fatty acids with more than one double bond 
along the chain are called PUFAs. Each following double bond is usually three carbon atoms 
farther from the previous double bond. However, the total number of double bonds never 
exceeds six, as this total number depends on the overall chain length. Fatty acids with more 
than 18 carbon atoms have double bonds at only n-3, n-6, and n-9. 
 
1.3 Omega-3 
Notably, n-3 and n-6 PUFAs can only be synthesized by plants and marine phytoplankton 
(14). In general, n-3 PUFAs are characterized by a chemical structure that includes double 




types of PUFAs are the very-long-chained fatty eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA), which are abundant in different marine sources, such as fish oil 
and algae. These PUFAs are important precursors to eicosanoids, such as prostaglandins, 
leukotrienes, and thromboxanes, which are paracrine hormones that modulate several 
inflammatory processes. Many of their functions are associated with the size of the blood 
vessels, permeability and activity of membrane-bound enzymes, and receptor and signal 
transduction (13). They influence several inflammatory processes and the activity of platelets, 
which in turn causes blood clotting. These are functions that are physiologically associated 




Figure 1. The omega-3 (n-3) structure and source. 





1.4 Essential fatty acids 
Neither humans nor animals can synthesize fatty acids with double bonds less than nine atoms 
away from the terminal methyl group (12). These fatty acids that humans cannot synthesize, 
and at the same time need to maintain several important biological functions, are called 
essential fatty acids, which are n-6 linoleic acid (LA) and n-3 ⍺-linolenic acid (ALA). In 
general, n-6 LA can be stepwise desaturated and elongated to form arachidonic acid (AA; 
Figure 2). Notably, AA is a precursor to a vasoconstrictor and potent platelet aggregator 
[thromboxane (𝐴2)]; a vasodilator and platelet antiaggregator [prostaglandin (𝐸2)]; and a 
leukotriene chemotaxis, adherence, and inflammation inducer [leukotriene (𝐵4)] (14, 17). 
Using the same mechanisms, n-3 ALA can form DHA and the anti-inflammatory EPA. 
Furthermore, EPA is a precursor to a weak platelet aggregator and vasoconstrictor 
[thromboxane (𝐴3)], a vasodilator and platelet antiaggregator [prostacyclin (𝑃𝐺𝐼3)], and 
leukotriene (𝐵5), which is a weak chemotactic agent and inflammation inducer. Both males 
and females can convert up to 8% and 21%, respectively, of DHA from ALA (13). The 
conversion rate is associated with the intake of both EPA and DHA as well as the intake of 
LA and ALA. It has been shown that 2 g of DHA every day is superior to the same amount of 
EPA for erythrocyte membrane incorporation of both EPA and DHA. The proportion of 
longer-chain n-3 PUFAs over six weeks does not increase with 4 g of ALA every day. Most 
human studies using radioactive tracers have not shown any major impact on ALA conversion 






Figure 2. Anabolic pathway of essential fatty acids.  
Adapted and modified from Nakamura et al. (2003) (18). 
 
Both n-3 and n-6 PUFAs compete for the same elongase and desaturase proteins, which is 
why ratios seem to play a role when assessing the health benefits (Figure 2) (18). Some 
studies have suggested that balancing between n-3 and n-6 PUFAs is important to regulate 
inflammation (19-21). Anti-inflammatory, antiplatelet, and hypotensive effects may be 
mediated by competition with AA for the synthesis of eicosanoids by cyclooxygenase. 
Humans have evolved on a diet with an n-6/n-3 PUFA ratio of 1, while modern western diets 
are known to be excessively rich in n-6 PUFAs, resulting in proinflammatory ratios between 




prothrombotic and proaggregatory, thus increasing blood viscosity and vasoconstriction. 
Reduced bleeding times have been found in patients with MI. Higher n-6/n-3 PUFA ratios in 
platelet phospholipids have been associated with higher CVD-related mortality rates (20). 
Ratios of 2:4 to 3:1 have been suggested as optimal (14). It should be noted that the absolute 
intake levels and ratios are often different between studies, complicating their interpretation 
(13). It should be noted that the absolute intake levels and ratios are often different between 
studies, complicating their interpretation (13). However, absolute intake seems to be more 
important given that the nutritional requirements are otherwise covered. The production of 
proinflammatory factors decreases with lower n-6/n-3 PUFA intake ratios. However, 
excessive total intake of PUFAs provokes several adverse effects, such as impaired immune 
function, increased bleeding tendency, and lipid peroxidation (22). 
 
1.5 Essential fatty acid deficiency 
Essential fatty acids have several important physiological functions, such as the maintenance 
of the water-permeability function of the skin to avoid excessive transepidermal water loss 
and preserve energy by decreasing water evaporation (13). Essential fatty acid deficiency in 
adults is rare, and the minimum requirements are still unknown.  
DHA may be important in the development of normal visual function, as high concentrations 
of DHA have been found in the synapses in the central nervous system and in the rod outer 
segment of the photoreceptor cells of the retina (13). Studies on preterm infants have also 
suggested that DHA is important for psychomotor development. Administering long-chain 
n-3 PUFAs during pregnancy improves the n-3 PUFA status and mental development of the 
fetus or newborn. 
It has also been suggested that administering <0.05 energy percent (E%) ALA during enteral 
nutrition and <0.1 E% ALA during parenteral nutrition causes skin changes (13). Moreover, 
skin changes and growth retardation have been observed among healthy newborns that were 




1.5.1 Dietary sources 
ALA is an essential 18-carbon n-3 PUFA that is derived from plant sources, with the main 
source being vegetable oils, such as rapeseed oil, camelina oil, and flaxseed oil (13, 16). Other 
sources include soybeans, hemp seeds, and walnuts. Eggs may contain long-chain n-3 
PUFAs, depending on what the animals are fed. LA is another essential 18-carbon n-6 PUFA 
commonly found in nuts and seeds. Seafood is the primary source of long-chain n-3 PUFAs 
(EPA and DHA).  
 
1.5.2 Fatty acid intake recommendations 
In Norway, dietary recommendations are mainly based on the Nordic Nutrition 
Recommendations 2012 (13, 23). The recommended intake of MFAs is 10–20 E%, whereas 
that of PUFAs is 5–10 E%. The recommended intake of SFAs, trans-fatty acids (TFAs), and 
n-3 PUFAs is <10 E%, as low as possible, and ≥1 E%, respectively. In general, the total fat 
intake should stay within the range of 25–40 E%. These are the general recommendations for 
adults and children aged two and above. 
In Norway, fish oils have traditionally been classified as a food instead of a supplement (13). 
Such oils are recommended as a source of marine EPA, DHA, and vitamin D, and various 
health authorities often recommend their use in specific periods of life, such as during 
childhood or pregnancy or for frail older individuals. Pregnant women are advised to ingest 
10 μg of vitamin D per day during the winter when there is little sunlight in the northern 
hemisphere (24). Cod liver oil contains vitamin D and is often used instead of other 
supplements containing vitamin D. In the Norwegian Women and Cancer (NOWAC) study 
performed by Brustad et al., it has been reported that approximately 35% of Norwegian 






1.6 Conflicting evidence on the benefit of omega-3 supplementation  
A broad literature search was performed during the spring of 2020 in PubMed, Medline, 
Cochrane Library, and Google Scholar to assess the current knowledge on the topic. For 
further details and description of the literature search, see Appendix 1. Updates were made 
during the fall.  
In the early 1970s, the low mortality rates of CHD among Greenland Eskimos sparked an 
interest in the protective effects of fish consumption (26, 27). Later studies have shown that 
moderate consumption of fish reduces the overall risk of CVD (28, 29). Moreover, it has been 
proposed that the two main constituents of marine n-3 PUFAs, EPA and DHA, are 
responsible for the observed beneficial effects, although it has also been suggested that the 
components exhibit a synergistic effect (high-quality proteins, amino acids, and vitamins). 
According to the Nurses’ Health Study, women who consume more fish and n-3 PUFAs are 
at a lower risk of CHD (30). Hence, fish oil supplements have become of major interest for 
both primary and secondary prevention of CVD. Some trials on primary prevention have 
revealed several clinical benefits of n-3 PUFA interventions, reducing the rate of CVD-related 
mortality (31, 32). In a case–control study performed by Yli-Jama et al., the authors showed 
that the percentage content of n-3 PUFAs in serum is inversely associated with the risk of MI 
(33).  
Several contradictory results suggest that n-3 PUFA interventions have no protective effect 
against cardiovascular outcomes (34-39). In a 2018 review performed by Abdelhamid et al., it 
was concluded that there is little to no evidence that EPA and DHA supplements have a 
protective effect on cardiovascular health, neither as primary nor as secondary prevention 
(40). The authors further pointed out that the benefits that have been previously suggested 
may have been obtained from trials with a high risk of bias. Other studies have found EPA 
and DHA protective against CVD among high-risk populations (41). Contrary, a 2013 
randomized controlled trial (RCT) found no reduction in cardiovascular mortality and 
morbidity in a group with multiple cardiovascular risk factors who were administered n-3 
PUFA supplements (42). 
In a 2018 meta-analysis performed by Aung et al., the authors found no supporting evidence 




(43). Manson et al. found no reduction in cardiovascular events among those who 
supplemented n-3 PUFAs. There was however a lower incidence of major cardiovascular 
endpoints (MI, stroke, or death from cardiovascular causes and invasive cancer) among those 
who supplemented n-3 PUFA and had low fish consumption (44).  
Generally, RCTs have mainly focused on the benefits of n-3 PUFA supplementation as a 
secondary prevention measure among patients with type 2 diabetes mellitus (T2DM) and 
prediabetes, as well as those with prevalent heart disease or a history of CVD events (45). 
However, the literature search suggests that the association between n-3 PUFA 
supplementation and primary prevention of CHD has not yet been investigated using an RCT 
study design. 
In a 2020 randomized controlled trial (RCT) by Kalstad and Myhre et al., the authors found 
no reduction in cardiovascular events or all-cause death in elderly patients with recent acute 
myocardial infarction (AMI) compare to placebo (46). Some researchers have suggested that 
an additional effect of n-3 PUFA supplements may be hard to detect because of the efficiency 














2 Research objectives 
This study aims to: 
• Examine the association between n-3 PUFA intake frequency and the risk of fatal 
myocardial infarction (FMI) in a cohort of the NOWAC study. 
• Assess the association between n-3 PUFA intake frequency and the risk of FMI within 
groups of high and low fatty fish intake. 
 
2.1 Research question 
The research question is as follows: Is there any association between n-3 PUFA 
supplementation frequency and the risk of FMI among healthy female adults (30–70 years of 














3 Materials and methods 
3.1 Study design 
This observational cohort study is based on prospective data from the NOWAC study, which 
is investigated using a quantitative research methodology.  
 
3.1.1 The Norwegian Women and Cancer Study 
The NOWAC study is a population-based cohort study that utilizes self-reported data 
obtained through questionnaires and already existing population registries (47). The study 
was initiated in 1991 to investigate the risk factors of breast cancer while paying attention to 
combined oral contraceptive use (48). The cohort consists of over 165,000 women aged 30–
70, randomly sampled from the national population register.  
The questionnaires contained two to eight pages of variables, such as smoking, menopause, 
physical activity, anthropometry, alcohol consumption, screening for breast cancer, 
socioeconomic status, sunbathing habits and pigmentation, and family history of breast cancer 
and disease (see Appendix 2). Data were included from questionnaires in which four out of 
the total number of pages contained questions regarding dietary habits. Food frequency 
questionnaires (FFQs) contained detailed questions regarding dietary habits during the 
preceding year across more than 90 different foodstuffs. Portion size was asked for some 
foods and the Norwegian weights and measures table were used to derive portions and 
weights (49).  
Women recruited in 1991-92 have answered one baseline and up to three follow-up 
questionnaires (Figure 3). In Figure 3, the blue boxes indicate the timing of enrollment and 
the number of women who were initially recruited, whereas the green, yellow, and red boxes 
indicate the second and third follow-up questionnaire mailings, respectively. The figure 
shows information about the number of participants, year of enrollment, and whether blood 
samples were obtained. Boxes with black frames represent the questionnaires included in the 




questionnaire was used for some of the participants who have already answered the first 
questionnaire, because the second questionnaire is more compatible with the later 
questionnaires, as the questionnaires collected in 1991–94 were shorter and had fewer diet-
related questions. The blue box (n=38,000) in the figure includes participants who answered a 
long questionnaire (Figure 3). The green box (n=29,000) with dotted lines includes 
participants who answered a shorter version of the questionnaire. 
 
 
Figure 3. Enrollment in the Norwegian Women and Cancer (NOWAC) study. 
 
 
3.1.2 Inclusion and exclusion criteria 
Women aged 30–70 at baseline, who completed the FFQs, were free of CVD at baseline, and 




Patients with self-reported hypertension, angina pectoris, T2DM, a history of stroke, a history 
of MI, and cancer at baseline were excluded from the analysis as primary prevention is of 
interest (Figure 4). The rationale was to exclude those receiving treatment, were likely on 
medication or had changed their dietary habits. There were 20,875 (289 cases) participants 
initially excluded due to this criterion. Those with fibromyalgia were, according to protocol, 
also supposed to be excluded. Data on fibromyalgia were however not obtainable. Another 6 
(0 cases) participants were excluded as a result of registered date of death before entry or at 
entry or emigration. The total lower and upper energy (kJ) intake were set to 2,500 and 
15,000 kJ, respectively. An additional 825 (6 cases) participants were therefore removed. This 
was done to address over- and under reporting of energy intake. The cut-off was chosen based 
on biological plausibility and NOWAC standards (50). Intake of fish and fish products above 
the 99th percentile (>292.28 g) was also excluded. This specific cut-off was set to manage 
overreporting across all fish intake variables and was determined by inspecting percentiles 
and the stem-and-leaf plot (see Appendix 3). It should be noted that a lower cut-off would 
exclude too many cases and reduce the statistical power. Hence, another 689 (4 cases) 
participants were excluded. In total, 22,395 participants were excluded from this study, 

































Women between 30 and 70 years 
who completed the FFQ. 
n=101,316 (555 cases) 
Excluded due to self-reported hypertension, angina 
pectoris, T2DM, previous stroke or MI, or cancer. 
n=20,875 (289 cases) 
Participants who fulfilled the initial 
inclusion criteria. 
n=80,441 (266 cases) 
Excluded due to registered date of death before entry, 
at entry, or emigration. 
n=6 (0 cases) 
n=80,435 (266 cases) 
Excluded du to energy (kJ) cut-off <2,500 kJ and 
>15,000 kJ. 
n=825 (6 cases) 
n=79,610 (260 cases) 
Excluded du to fish- and fish product intake above 
the 99th percentile (>292g). 
n=689 (4 cases) 
Participants included in the final 
analysis. 
n=78921 (256 cases) 




3.2 Statistical analysis 
All statistical analyses were performed using SPSS Statistics (Release 26.0.0.0; IBM Corp., 
Armonk, NY, USA) on Windows 10 (64-bit edition; Microsoft Corp., Redmond, WA, USA).  
The association between the incidence of FMI and n-3 PUFA supplementation frequency was 
evaluated using the proportional hazards (Cox) regression model (ℎ𝑖(𝑡) = 𝜆 (𝑡)  ∙
 𝑒(𝛽1𝑋1+ 𝛽2𝑋2+...)). Notably, hazards may vary over time, and the distribution throughout the 
length of the study represents the hazard function (51). The baseline hazard function is 
indicated by λ, and the exponentiated linear function contains the covariates (52).  
Descriptive statistics were used to find missing data and detect patterns, and to explore and 
summarize. SPSS tools like frequency tables, descriptive statistics, explore, and crosstabs 
were used. Percentiles and stem-and-leaf plots were evaluated. Missing data, extreme 
values/outliers, distribution of intake frequency groups, baseline characteristics, and mean 
intakes (before and after exclusion) was reported. Single imputations were made for missing 
values. Non-informative right censoring was applied. Follow-up times were calculated from 
enrollment till event, lost to follow-up or end of follow-up.  
The proportional hazards assumption was evaluated graphically by checking the Log (-log) 
plot. Tree models were constructed: a crude model (adjusted for age), a smoking adjusted 
model (adjusted for age and smoking), and a multivariate model that is adjusted for all 
covariates (age, smoking, BMI, self-reported health, education, menopausal status, breastfed 
at least one child, dietary covariates: fish and fish products, SFAs, fruit and vegetable intake). 
Hazard ratios (HRs) and confidence intervals (CIs) are reported for all three models. A trend 
test was conducted to look at trends across n-3 PUFA intake frequency groups within all the 
models by adding n-3 PUFA intake frequency as a continuous variable in each model.  
P-values are reported for trends. A complete case analysis was conducted to assess the 
robustness of the model. An interaction term for the main exposure variable (n-3 PUFA intake 
frequency) and time was added. The dataset was also split into two strata to look at the 
separate effect in high vs. low fatty fish intake groups as n-3 PUFA intake was expected to 





FMI was defined as the outcome variable. Cases were defined as participants with 
International Classification of Diseases, 10th Revision (ICD-10) code I21 on their death 
certificate, according to the Norwegian Cause of Death Registry: I21.0 (anterior wall ST-
elevation myocardial infarction [STEMI]), I21.1 (inferior wall STEMI), I21.2 (STEMI of 
other sites), I21.3 (STEMI of an unspecified site), I21.4 (non-ST-elevation myocardial 
infarction [nSTEMI]), and I21.9 (AMI, unspecified) (53). These were considered direct or 
underlying causes of death. The end of follow-up was on December 31, 2018. All participants 
were followed up for an average of 18.4 years. 
 
3.2.2 Exposure 
The exposure variable, n-3 PUFA, is based on the intake frequency of cod liver oil and 
generic fish oil (Table 1). Some questionnaires contained initial yes/no questions about 
whether or not the participant consumed an n-3 PUFA supplement. Supplements in both 
liquid and capsule form were included. The questions were stated somewhat differently in the 
questionnaires, and the participants reported average annual (12 months) and dichotomized 
seasonal intake (eight months for winter and four months for summer). Questionnaire 












Table 1. Questions about n-3 PUFA supplements and the original coding of values. 
Questions Time frame  Original values 




0 = Never/seldom 
1 = 1–3/month 
2 = 1/week 
3 = 2-3/week 
4 = 4–6/week 
5 = Daily 
How often do you consume liquid cod liver oil for 
the rest of the year? 
Summer 
(4 months) 




0 = Never/Seldom 
1 = 1-3/month 
2 = 1/week 
3 = 2-6/week 
4 = Daily 
How often do you consume liquid cod liver oil for 
the rest of the year? 
Summer 
(4 months) 




0 = Never/seldom 
1 = 1–3/month 
2 = 1/week 
3 = 2-3/week 
4 = 4–6/week 
5 = Daily 
How often do you consume cod liver oil capsules for 
the rest of the year? 
Summer 
(4 months) 




0 = Never/Seldom 
1 = 1-3/month 
2 = 1/week 
3 = 2-6/week 
4 = Daily 
How often do you consume cod liver oil capsules for 
the rest of the year? 
Summer 
(4 months) 




0 = Never/seldom 
1 = 1–3/month 
2 = 1/week 
3 = 2-3/week 
4 = 4–6/week 
5 = Daily 
How often do you consume cod liver oil/fish oil 
supplements in the winter? 
Winter 
(8 months) 
0 = Never/Seldom 
1 = 1-3/month 
2 = 1/week 
3 = 2-6/week 
4 = Daily 
How often do you consume cod liver oil /fish oil 
supplements for the rest of the year? 
Summer 
(4 months) 
Abbreviations: n-3, omega-3; PUFA, polyunsaturated fatty acid. 
 
 
All variables were initially standardized to 1 (never/seldom), 2 (1–3/month), 3 (1/week), 4 (2–
6/week), and 5 (daily). Winter and summer variables were weighted, respectively, as 0.66  
(8 months/12 months) and 0.33 (4 months/12 months) into annual means. The total mean 
values of all annual variables for each participant were calculated into one variable. All 




1 (never) if also true for dichotomized yes/no variables. All values between 1 and 5 (1.001 




All initial covariates were chosen depending on relevance and available data. These 
covariates included age (scale: years), parity (scale: number of children), smoking (scale: 
pack-years, nominal: status combined; 1 = never, 2 = former, 3 = current [1–20 pack-years], 4 
= current [21–66 packyears]), physical activity score as ordinal data (1–10 grouped; 1 = 
inactive [1–3], 2 = moderately inactive [4-5], 3 = moderately active [6-7], 4 = active [8–10]), 
body mass index (BMI) as ordinal data (1 = underweight [<20 kg/m2], 2 = normal weight 
[20–25 kg/m2], 3 = overweight [25–30 kg/m2], 4 = obesity [>30 kg/m2]), self-reported health 
(1 = bad, 2 = good, 3 = very good), educational level as ordinal data (1 = <10 years, 2 = 10–
12 years, 3 = >12 years), menopausal hormone therapy (MHT) as ordinal data (1 = never, 2 = 
former, 3 = current), postmenopausal status as nominal data (yes/no), breastfeeding as 
nominal data (ever breastfed at least one child, yes/no), and dietary intake variables as 
continuous data (grams per day; total intake of fatty fish, fish and fish products, lean fish, 
total fatty acids, SFAs, fruits, and vegetables).  
In a 2020 study performed by Kravdal et al., the authors found that parity has a protective 
effect against CVD in a Norwegian population (54). BMI is known to be associated with MI. 
In their meta-analysis, Zhu et al. concluded that both overweight and obesity increase the risk 
of AMI (55). In addition, it has been established that smoking and physical inactivity increase 
the risk of MI (50) and that higher fruit and vegetable consumption is associated with a lower 
risk of CVD (8, 56). In a study by Barger et al., the authors found that self-rated health is 
associated with CVD-related risk of mortality (57). It has also been reported that the 
educational level is associated with the socioeconomic status (58, 59). Several researchers 
have found some correlation between CVD and menopausal status, and it has also been 




In a meta-analysis performed by Zheng et al., the authors concluded that low (one serving per 
week) or moderate (two to four servings per week) fish consumption has a significant 
beneficial effect on CHD compared to less than one serving per month or one to three 
servings per month (29). Moreover, Jayedi et al. revealed potential regional differences in the 
association between fish consumption and CVD (62). The American Heart Association 
recommends eating fish at least twice a week and stipulates that consuming oily fish is useful 
for the heart (63). 
With regard to CVD outcomes, it seems that SFA intake is of greater importance than total 
fatty acid intake. A Cochrane systematic review reported a reduction in all cardiovascular 
events resulting from reducing the intake of saturated fats (64). A protective effect resulting 
from the reduction of total fat intake has also been reported, although the effect observed was 
less pronounced than that of altering the composition (65).  
 
3.2.4 Model building 
Predictors were added using the force entry method, which is called Enter in SPSS Statistics. 
All covariates were tested in the proportional hazards model independently against the 
dependent variable, with a cut-off significance level of p ≤ 0.20. All independent variables 
except for MHT and fatty fish intake were statistically significant; therefore, MHT and fatty 
fish intake were excluded. Covariates were also checked for multicollinearity (see Appendix 
4). As suggested by Andy Field, Pearson’s correlations of r ≥ 0.80 are high; therefore, a cut-
off of r = 0.70 was set to reduce standard errors and avoid untrustworthy b coefficients (66). 
Notably, parity and physical activity did not contribute to the overall model. However, a 
correlation between lean fish intake and total fish intake was found (r = 0.73); thus, lean fish 
intake was excluded as it contributed less to the model. The same was true for total fatty acid 
intake and SFA which correlated (r = 0.95). SFA was kept in the model as it seems to be more 
associated with FMI compared to total fatty acid intake (64). Thus, lean fish intake was 
excluded from the model. The rationale behind excluding physical activity was that its 
significance vanished once fruit intake was included. This may be the result of physically 




Three regression models were presented: crude, smoking-adjusted, and multivariate-adjusted. 
The crude model was adjusted for age, the smoking-adjusted model was adjusted for both age 
and smoking, and the smoking-adjusted model was included as smoking is significantly 
associated with MI (56). Pack-years are used, which is the number of packs of cigarettes 
smoked per day times the number of years smoked (67). The multivariate model includes all 
the final covariates that contributed to the model: age, smoking, BMI, self-reported health, 
education, menopausal status, breastfed at least one child, dietary covariates: fish and fish 
products, SFA, fruit, and vegetable intake. The multivariate model included all the final 
covariates that contributed to the model: age, smoking, BMI, self-reported health, educational 
level, menopausal status, breastfeeding at least one child, and dietary covariates (fish and fish 
products, SFAs, fruit, and vegetable intake). 
 
3.2.5 Missing data 
All variables with missing values are reported in tables (Table 2). Single imputation was used 
for missing variables. Variable means were used as a replacement for missing values of 
height, weight, physical activity, educational level, and pack-years. Missing information on 
smoking status was coded as 1 (never). Pack-year mean based on either former, current or 
both combined were similar and did not affect the grouping on the variable used in the model. 
As for hypertension, angina pectoris, T2DM, stroke, and MI, missing dichotomous (yes/no) 
information on a specific health variable was coded as 0 (no disease). The coding of the 
exposure variable is previously explained (section 3.2.2). Missing values on self-reported 
health, 1=very bad, 2=bad, 3=good, and 4=very good, was imputed 2=good. Missing values 
on self-reported health (1 = very bad, 2 = bad, 3 = good, 4 = very good) were coded as 2 
(good). Missing information on smoking status, hormone therapy, and breastfeeding was 







Table 2. Missing values before imputations and exclusions. 
Before exclusion Mean Median SD Valid Missing 
Height 166.1 166 5.7 100,203 1,113 
Weight 68.4 67 11.6 99,185 2,131 
Packyears’ (former smokers) 6 3 7 34,368 66,948 
Packyears’ (current smokers) 14.7 14 8.6 29,411 71,905 
Education 12 11 3.5 95,414 5,902 
Physical activity 5.5 5 1.8 91,615 9,701 
Hypertension    86,301 15,015 
Angina pectoris    80,059 21,257 
Diabetes    80,243 21,073 
Stroke    79,769 21,547 
MI    79,897 21,419 
Self-reported health    85,957 15,359 
Physical health    11,731 89,585 
Smoking    99,963 1,353 
MHT    97,980 3,336 
Prevalent cancer    96,900 4,416 
Breastfeeding*    92,461 8,855 
Abbreviations: MHT, menopausal hormone therapy; MI, myocardial infarction;  
T2DM, type 2 diabetes mellitus. 
*Among those who reported having children 
 
 
3.3 Ethical considerations 
The NOWAC study was approved by the Norwegian Data Protection Authority and Regional 
Committees for Medical Health Research Ethics. All the data necessary for this project were 
provided by the research team of the NOWAC study at the Institute of Community Medicine, 
Medical Faculty, University of Tromsø. Written informed consent was obtained from each 
participant, and ethical approval for the study was obtained from the Regional Ethical 





3.3.1 Privacy and confidentiality 
It should be pointed out that the dataset will not contain any patient identifiers and will be 
kept on a password-protected computer throughout the research period. All data will be safely 
removed from the computer after the research is published. 
 
3.3.2 Conflict of interest 


















Out of a total of 101,316 eligible Norwegian women, with a mean age of 52.2 years and a 
range of 41–76 years, 22,395 subjects were excluded. 
 
4.1 Baseline characteristics across omega-3 polyunsaturated fatty 
acid intake frequency groups 
The following is the distribution of participants across n-3 intake frequencies: 40%, 38%, and 
22% for never, intermittent, and daily, respectively (Figure 5). Most of the participants (40%) 
reported that they never consumed n-3 PUFA supplements. Those who consumed n-3 PUFA 
supplements on a daily basis represented the lowest proportion (22%). 
 
 
Figure 5. Study population distribution across omega-3 (n-3) polyunsaturated fatty acid 






The mean age across all n-3 PUFA intake frequency groups was 51 years (±6.4; Table 3), and 
the baseline characteristics were somewhat similar across all groups. Those who never 
consumed n-3 PUFA supplements were younger (51 years) than those with intermittent (52 
years) and daily (52.8 years) intake. The body weight values of those who never consumed 
n-3 PUFA supplements were slightly higher than of those with intermittent and daily intake: 
68, 67, and 67 kg, respectively.  
Postmenopausal status was reported among 42% of the participants, and 85% reported 
breastfeeding (Table 3). The educational level and self-reported health were also similar 
across the groups. Those who received education for more than 12 years represented 39% of 
the total sample. 
 
4.1.1 Dietary characteristics 
The energy intake in the intermittent and daily groups was found to be 7,108 and 7,242 kJ, 
respectively. The lowest energy intake (6,772 kJ) was found among those who never 
consumed n-3 PUFA supplements (Table 3). Those with daily n-3 PUFA supplement intake 
reported a mean total fatty acid intake value of 35 E%, which is slightly higher than the values 
of the never and intermittent groups (i.e., 34 E% and 34 E%, respectively). Although 
macronutrient intake was similar across all three groups, the fatty acid intake profile in the 
daily group differed from that in the never and intermittent groups as they consumed less 
SFAs and TFAs and more MFAs and PUFAs. Moreover, the consumption of fruits, 
vegetables, and fatty fish was found to be higher among the daily group. Mean consumption 
of 181, 193, and 228 g of fruits per day was reported among the never, intermittent, and daily 
groups, respectively. Vegetable intake was found to be 132, 135, and 154 g/day, and fatty fish 
intake was found to be 14, 16, and 17 g/day. 
 
4.1.2 Lifestyle characteristics 
The smoking status for each level of intake frequency was also uniformly distributed, 
although those who never consumed n-3 PUFA supplements comprised the greatest 
proportion of those who reported 20–66 pack-years (7%; see Table 3). Both the intermittent 




active (score: 7–10) participants was higher in the daily group (17%) than in the never and 
intermittent groups (13% and 13%, respectively). The daily group also had a low proportion 
of inactive (score: 1–3) participants compared to the never and intermittent groups: 12%, 
10%, and 9%, respectively. 
 
 
Table 3. Baseline characteristics according to n-3 PUFA intake frequency (never, intermittent 
and daily) after exclusion. 
 
Characteristics Never Intermittent Daily Total 
 (n=31,348) (n=29,857) (n=17,716) (n=78,921)      
N (%) 40 38 22 100 
Age (years) 51 52 53 51 ± 6 
Height (cm) 166 166 166 166 ± 6 
Weight (kg) 68 67 67 67 ± 11 
Number of children 2 2 2 2 ± 1 
BMI (kg/m2) 25 24 24 24 ± 4 
Total energy (kJ/day) 6,772 7,108 7,242 7,004 ± 1867      
Education level (%)     
<10 years 24 23 21 23 
10-12 years 39 36 38 38 
>12 years 37 41 39 39 
 
BMI (kg/m2) (%) 
     
Underweight (<20) 7 7 7 7 
Normal weight (20–25) 60 64 64 62 
Overweight (25–30) 25 23 23 24 
Obese (>30) 8 6 6 7      
Physical activity (%)     
Inactive (1-3) 12 10 9 11 
Moderately inactive (3-5) 45 44 40 43 
Moderately active (5-7) 31 33 34 32 
Active (7-10) 13 13 17 14      
Smoking status (%)     
Never 35 38 36 36 
Former 33 34 37 34 
Current (1-20 packyears) 25 23 21 23 
Current (20-66 packyears) 7 6 7 7      
Self-reported health (%)     
Bad 6 6 6 6 
Good 62 62 63 62 




Characteristics Never Intermittent Daily Total 
 (n=31,348) (n=29,857) (n=17,716) (n=78,921) 
MHT status (%)     
Never 70 70 60 68 
Former 10 9 15 11 
Current 20 21 25 22      
Breastfed (%)     
No 15 15 17 15 
Yes 85 85 83 85      
Menopausal status (%)     
Pre 62 59 49 58 
Post 39 41 51 42      
Dietary intake (g/day)     
Fish and fish product 88 98 99 94 ± 53 
Lean fish 27 31 29 29 ± 27 
Fatty fish 14 16 17 15 ± 16 
Fruits 181 193 228 196 ± 148 
Vegetables 132 135 154 138 ± 89      
Macronutrients (E%)     
Total fatty acids 34 34 35 34 ± 12 
SFAs 14 14 13 14 ± 5 
TFAs 0.7 0.7 0.6 0.7 ± 0.3 
MFAs 11 11 11 11 ± 4 
PUFAs 6 6 6 6 ± 3 
Abbreviations: BMI, body mass index; E%, energy percent, MFA, monounsaturated fatty acid; MHT, menopausal 
hormone treatment; n-3, omega-3; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid; TFA, trans-fatty 
acid. 




4.1.3 Fish consumption 
After exclusion, the mean intake of fish and fish products was found to be 94 g (±53; Table 
4). The maximum intake of fish and fish products and fatty fish decreased from 893 to 292 g 
and from 495 to 197 g, respectively, and the maximum intake of total fatty acids decreased 
from 298 to 194 g. However, the fish and fish products and caloric intake cut-off did not 





Table 4. Dietary intake before and after applying the exclusion criteria. 
 Before exclusion   After exclusion  
      
Dietary intake (g/day) Mean ± SD Max  Mean ± SD  Max 
Fish and fish product 98 ± 60 893  94 ± 53 292 
Lean fish 31 ± 30 245  30 ± 27 245 
Fatty fish 16 ± 19 495  15 ± 16 197 
Fruits 196 ± 150 972  196 ± 148 972 
Vegetables 138 ± 92 983  138 ± 89 983 
Total fatty acids 63 ± 23 298  64 ± 22 194 
SFAs 25 ± 10 131  26 ± 10 97 
TFAs 1.2 ± 0.5 7  1.2 ± 0.5 6 
MFAs 20 ± 7 85  20 ± 7 63 
PUFAs 12 ± 5 90  12 ± 5 63 
Total energy (kJ/day) 6,931 ± 1,994 29,104  7,005 ± 1,867.3 14,984 
Abbreviations: MFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid 
SFA, saturated fatty acid; TFA, trans-fatty acid. 
Note: Participants with fish and fish products intake above the 99th percentile and 
caloric intake of <2,500 and >15,000kJ were excluded.  







4.2 Cox proportional hazards: Model assumptions 
4.2.1 Proportional hazards over time 
It can be concluded that the proportional hazards assumption was fulfilled. The log (–log) 
graph indicated that there are proportional hazards between groups over time (Figure 6). 
 
 
Figure 6. Illustration of the proportional hazards over time (observation years). 
 
4.2.2 Interaction between the main covariate and time 
No statistically significant interaction was found between the exposure variable and the time-
dependent covariate (p = 0.89; Table 5). 
 
Table 5. Interaction between n-3 PUFA intake frequency and time. 
 
 B SE Wald df Sig. Exp(B) 
n-3 PUFA intake frequency -.009 .210 .002 1 .966 .991 
n-3 PUFA intake frequency × T_COV_ .002 .015 .018 1 .894 1.002 
Abbreviations: n-3, omega-3; PUFA, polyunsaturated fatty acid. 





4.3 The association between omega-3 intake frequency and the risk of 
fatal myocardial infarction 
Data from 78,921 women were analyzed. During the 1,453,384 person-years of follow-up 
(average: 18.4 years), a total of 256 FMI cases were identified. The incidence rate was found 
to be 17 per 100,000. Hazard ratios (HRs) were estimated using the Cox proportional hazards 
model by comparing the intake frequencies. Estimates were calculated for intermittent and 
daily intake, with those who never consumed n-3 PUFA supplements as the reference group. 
Estimates for the crude, smoking-adjusted, and multivariate-adjusted models are presented in 
Table 6. 
 
Table 6. Cox proportional HRs (95% CI) for the association between n-3 PUFA intake and 
the risk of FMI. 
 HR (95% CI)  
Intake frequency Never Intermittent Daily Sig. 
N 31,348 29,857 17,716  
Cases 95 110 51  
Crude model 1 [Ref.] 0.86 (0.65–1.14) 0.71 (0.50–1.00) 0.05 
Smoking-adjusted* 1 [Ref.] 0.89 (0.67–1.17) 0.76 (0.54–1.20) 0.11 
Multivariate-adjusted** 1 [Ref.] 0.95 (0.72–1.26) 0.85 (0.60–1.20) 0.39 
Abbreviations: BMI, body mass index; CI, confidence interval; FMI, fatal myocardial 
infarction; HR, hazard ratio; n-3, omega-3; PUFA, polyunsaturated fatty acid; SFA, 
saturated fatty acid. 
Note: p-values for the trend tests are presented in the Sig. column.. 
*Adjusted for age and smoking. 
**Adjusted for age, smoking, BMI, self-reported health, educational level, menopausal status, 
breastfeeding at least one child, and dietary covariates (fish and fish products, SFAs, fruits 




The crude model showed an HR for FMI of 0.86 (95% confidence interval [CI]: 0.65–1.14) in 
the intermittent group and a borderline statistically significant HR of 0.71 (95% CI: 0.50–
1.00) in the daily group (Table 6). The age- and smoking-adjusted models showed HRs of 
0.89 (95% CI: 0.67–1.17) and 0.76 (95% CI: 0.54–1.20) for the intermittent and daily intake, 
respectively, of n-3 PUFA supplements. The multivariate model, adjusted for age, smoking, 




child, and dietary covariates (i.e., fish and fish products, SFAs, fruits, and vegetables intake), 
showed HRs of 0.95 (95% CI: 0.72–1.26) and 0.85 (95% CI: 0.60–1.20) for intermittent and 
daily intake, respectively. The overall trend for the crude model was borderline significant  
(p = 0.05). Trends for the smoking-adjusted and the multivariate-adjusted model are 
statistically insignificant (p = 0.11 and 0.39, respectively). Figure 7 is a graphical 




Figure 7. Cumulative survival in omega-3 (n-3) polyunsaturated fatty acid (PUFA) intake 







A complete case analysis with no imputations was also performed to assess the robustness of 
the primary analysis (68, 69). Estimates for the crude, smoking-adjusted, and multivariate-
adjusted models are presented in Table 7. The effect estimates were found to be similar to the 
results in the previous model with imputations on missing variables. 
 
Table 7. Complete case analysis: Cox proportional HRs (95% CI) for the association between 
n-3 PUFA intake and the risk of FMI. 
 HR (95% CI)  
Intake frequency Never Intermittent Daily Sig. 
N 25,989 16,024 14,802  
Cases 70 38 38  
Crude model 1 [Ref.] 0.71 (0.48–1.06) 0.70 (0.47–1.05) 0.06 
Smoking-adjusted* 1 [Ref.] 0.76 (0.51–1.14) 0.76 (0.51–1.14) 0.15 
Multivariate-adjusted** 1 [Ref.] 0.92 (0.57–1.46) 0.84 (0.52–1.37) 0.49 
Abbreviations: BMI, body mass index; CI, confidence interval; FMI, fatal myocardial 
infarction; HR, hazard ratio; n-3, omega-3; PUFA, polyunsaturated fatty acid; SFA, 
saturated fatty acid. 
*Adjusted for age and smoking. 
**Adjusted for age, smoking, BMI, self-reported health, educational level, menopausal status, 
breastfeeding at least one child, and dietary covariates (fish and fish products, SFAs, fruits 




4.3.2 Assessing the risk within groups of high and low fatty fish intake 
The dataset was divided into two strata according to the median intake of fatty fish (11 g/day; 
Table 8). Both the crude and smoking-adjusted models showed HRs of 0.54 (95% CI: 0.32–
0.90) and 0.57 (95% CI: 0.34–0.95), respectively, for the daily intake of n-3 PUFAs among 
those with low fatty fish intake. The protective effect was, however, statistically insignificant 
in the multivariate-adjusted model, with an HR of 0.65 (95% CI: 0.39–1.09). The survival 
curves for those with high fatty fish intake indicate lower survival rates for those with daily n-
3 PUFA intake than for those in the intermittent and never groups (Figure 8). However, the 




Table 8. High and low intake of fatty fish: Cox proportional HRs (95% CI) for the association 
between n-3 PUFA intake and the risk of FMI. 
 HR (95% CI) 
Fatty fish intake   Low High 
 Never Intermittent Daily Intermittent Daily 
N 31,348 14,566 7,962 15,291 9,754 
Cases 95 59 20 51 31 
Crude model 1 [Ref.] 0.85 (0.59–1.23) 0.54 (0.32–0.90) 0.90 (0.59–1.38) 0.94 (0.58–1.51) 
Smoking-adjusted* 1 [Ref.] 0.88 (0.61–1.27) 0.57 (0.34–0.95) 0.93 (0.60–1.42) 1.02 (0.63–1.66) 
Multivariate-adjusted** 1 [Ref.] 0.96 (0.66–1.39) 0.65 (0.39–1.09) 0.98 (0.64–1.51) 1.12 (0.68–1.82) 
Abbreviations: BMI, body mass index; CI, confidence interval; FMI, fatal myocardial 
infarction; HR, hazard ratio; n-3, omega-3; PUFA, polyunsaturated fatty acid; SFA, 
saturated fatty acid. 
Note: Low=<11 gram/day, high=>11 gram/day. 
*Adjusted for age and smoking. 
**Adjusted for age, smoking, BMI, self-reported health, educational level, menopausal status, 
breastfeeding at least one child, and dietary covariates (fish and fish products, SFAs, fruits 

























Figure 8. Cumulative survival in omrga-3 (n-3) polyunsaturated fatty acid (PUFA) intake 





Figure 9. Cumulative survival in omega-3 (n-3) polyunsaturated fatty acid (PUFA) intake 





4.3.3 Checking for interaction 
Interaction (effect-modification) can be seen if the effect between the primary exposure group 
and the outcome differs among strata (70). An interaction term was included in the 
multivariate model to check whether fatty fish intake affects the relationship between the n-3 
PUFA supplementation frequency and the risk of FMI as an effect modifier (Table 9). The 
overall interaction effect was found to be statistically insignificant (p = 0.34). 
 
Table 9. Cox proportional HRs (95% CI) with interaction term for n-3 PUFA frequency and 
fatty fish intake. 
 HR (95% CI)  
Intake frequency Never Intermittent Daily Sig. 
N 31,348 29,857 17,716  
Cases 95 110 51  
Multivariate-adjusted model 1 [Ref.] 0.83 (0.57–1.20) 0.69 (0.43–1.10) 0.29 
Interaction term* 1 [Ref.] 1.01 (0.99–1.02) 1.01 (0.99–1.03) 0.34 
Abbreviations: BMI, body mass index; CI, confidence interval; FMI, fatal myocardial 
infarction; HR, hazard ratio; n-3, omega-3; PUFA, polyunsaturated fatty acid; SFA, 
saturated fatty acid. 
Note: Interaction term added to the model: n-3 PUFA intake frequency × fatty fish intake 
(g/day). Adjusted for age, smoking, BMI, self-reported health, educational status, menopausal 
status, breastfeeding at least one child, and dietary covariates (fish and fish products, fatty 













Although the potential health benefits of n-3 PUFA supplementation have been studied since 
the 1970s, research has not yet provided enough evidence supporting the claim that n-3 PUFA 
supplements can protect against CVD. This is the first study to assess the association between 
n-3 PUFA intake frequency and FMI among women in the NOWAC study.  
 
5.1 Main findings 
No associations between n-3 PUFA intake frequency and the risk of FMI in the NOWAC 
study was found. This evaluation remains after adjusting for necessary confounding factors. 
The results of this study showed that the baseline characteristics were similar across all three 
intake groups (never, intermittent, and daily). A gradient was observed due to decreasing 
effect sizes with increased intake frequency. However, the effect sizes were small, and the 
confidence intervals contained the point of null effect. Also, the trends for the smoking-
adjusted and the multivariate-adjusted models were statistically insignificant (p = 0.11 and 
0.39, respectively).  
The fatty fish intake stratified model showed statistically significant negative associations 
between daily n-3 PUFA supplement intake and FMI in the low fatty fish intake strata, 
according to both the crude and smoking-adjusted models. The effect, however, disappeared 
when all the confounders were adjusted for. The difference observed between the fatty fish 
intake groups (high and low) suggests effect modification. Thus, an interaction term was 
added to the model, which was statistically insignificant (p = 0.34).  
 
5.2 Assessment of the methodological quality 
5.2.1 Missing data 
The dataset contained missing data on participants. In general, missing data can lead to loss of 
information and systematic errors in epidemiological studies (68). Researchers usually 




regarding the necessary variables. If data are not missing completely at random, complete 
case analysis on its own may be biased. However, the data in the present study are not 
missing completely at random. Single and multiple imputations are methods that are often 
used to account for missing data; however, they may introduce serious bias. Although 
multiple imputations are computationally demanding, it has the potential to improve the 
validity of research, given that modeling is performed appropriately. Single imputation 
methods may lead to systematic errors and underestimation of the true variability of the data 
(69). Generally, single imputation is performed for each missing value, which means that each 
missing value is replaced by either the mean or median within the respective variable. This 
method was chosen to maintain the sample size and statistical power and reduce bias. 
Multiple imputations were not performed because it requires much more advanced statistical 
modeling of each variable with a missing value, and the validity would improve only if it is 
performed properly. Since it is impossible to determine the level of randomness of the 
missing data as well as the uncertainties tied to the missing input variables, a sensitivity 
analysis was performed. Effect estimates were, therefore, compared between a complete case 
analysis and a model with single imputation. The results showed that the impact on the effect 
estimates was reasonably small, thus improving the prediction of the analysis and confirming 
the model robustness.  
 
5.2.2 Strengths 
The main strength of this study is its longevity and prospective design. Moreover, the data on 
the outcome (FMI) can be considered reliable, thanks to the national population register. In a 
study performed by Mahapatra et al., the authors evaluated the quality of civil registration 
systems. According to that study, the Norwegian death registration data were classified as 
medium with a completeness level of 70%–90% (83). According to a study by Phillips et al., 
Norway scored 87.6 out of 100 points, the lowest value between all Nordic countries (84). 
According to these studies, the use of unspecified codes is the main issue in the Norwegian 
cause of death registry. Nevertheless, the cause of death is reported by health professionals 
and the data are considered reliable. In a study by Lund et al., the authors found an almost 
identical cumulative incidence of all types of cancer when they compared NOWAC and 




It has been suggested that effective medication and/or treatment is the reason why modern 
research has not presented enough evidence supporting the claim that n-3 PUFA supplements 
have a protective effect against CVD (30, 37, 38). This problem was addressed by excluding 
subjects with hypertension, angina pectoralis, T2DM, stroke, and MI. Excluding those 
subjects likely also excluded most of those who consume statins, β-blockers, angiotensin-
converting enzyme (ACE) inhibitors, aspirin, and similar preventive medication. Aspirin 
(acetylsalicylic acid) generally decreases the risk of CHD in part by blocking the 
cyclooxygenase enzyme that converts AA into thromboxane, which in turn inhibits platelet 
aggregation (71, 72). Acetylsalicylic acid is primarily used as a secondary prevention method. 
Jortveit et al. found that 97% of patients with STEMI and 91% of those with nSTEMI who 
were discharged were prescribed acetylsalicylic acid. Adenosine diphosphate (ADP) receptor 
inhibitors, β-blockers, statins, ACE inhibitors, and angiotensin II (AII) receptor inhibitors are 
also commonly used as secondary prevention methods after MI (Table 10). Dale et al. found 
that 10.1% of women with chronic pain and 4.7% of those without chronic pain use over-the-
counter acetylsalicylic acid (73).  
 




(n = 3,429) 
nSTEMI 
(n = 8 557) 
 Number (%) Number (%) 
Acetylsalicylic acid 3,250 (97)  7,745 (91)  
ADP-receptor inhibitors 3,083 (92)  6,349 (74)  
β-blockers 2,754 (82)  6,788 (79)  
Statins 3,073 (92)  6,942 (81)  
ACE/AII receptor inhibitors 2,047 (61)  4,441 (52)  
Abbreviations: ACE, angiotensin-converting enzyme; ADP, adenosine diphosphate; AII, 
angiotensin II; MI, myocardial infarction; STEMI, ST-elevation myocardial infarction;  
nSTEMI, non-ST elevation myocardial infarction. 
Note: The table include cases with MI from all Norwegian hospitals in 2013 and is adapted 





Reverse causality can be a problem when interpreting the association if subjects have 
increased their n-3 PUFA supplement intake or altered any life-style factors due to a CVD 




One of the limitations of the present study is that exposure is measured by the intake 
frequency instead of weighted amounts. In a review conducted by Superko et al., the authors 
argued that including subjects who had n-3 PUFA levels below the therapeutic blood levels 
may decrease the beneficial effect on clinical endpoints (61). In the present study, it is 
assumed that the intake dosage correlates with the frequency, as fish and n-3 PUFA intake has 
previously shown good correlation with serum phospholipids levels in the NOWAC cohort 
(76). A positive effect may have been impossible to capture because of the frequency-based 
groups, as the intake dosage may vary within the higher-level groups. However, it is possible 
that the daily group comprised participants who take n-3 PUFA supplements more than once 
a day, which is impossible to adjust for due to the nature of the questionnaires. If there is a 
therapeutic cut-off level, it may as well require higher intake than what is recommended on 
the package. The general assumption is that most people follow the recommended dose.  
Another limitation was the limited amount of cases. A total of 256 FMI cases were kept in the 
analysis. Approximately 52% (289 cases) of all cases (total: 555) were excluded, mainly due 
to prevalent disease among participants. This limited the overall statistical power of the 
analysis. FMI was chosen instead of non-fatal MI to ensure reliable case reports. With self-
reported MI as the outcome variable, there would have been more events, but the necessary 
methodology would introduce a greater risk of systematic errors. 
 
5.2.4 Systematic error and validity 
Longitudinal cohort studies are considered among the superior epidemiological study designs 




degree a test measures what it is designed to test is called validity. Systematic and random 
error should therefore be kept as low as possible. The internal validity is an expression for the 
representability of an observation in the studied group. External validity is to what extent an 
observation is generalizable to a similar group outside the study population. 
Abdelhamid et al. argued that the benefits that have been suggested may have stemmed from 
trials with a high risk of bias (40). However, both information and selection bias were of little 
concern thanks to the prospective nature of the cohort. Nevertheless, not all the invited 
women returned the follow-up questionnaires (47). Low response rates may introduce 
selection bias, with a healthy volunteer effect. However, there was no reason to believe that 
there is a significant difference between the intake frequency of n-3 PUFA supplements and 
the risk FMI between those who returned the questionnaires and those who did not.  
The study population was randomly selected with the national identification number (47). 
Notably, the central population register in Norway contains samples of everyone living in the 
country for a short or long period of time and is continuously updated. Sampling bias was of 
little concern because of the highly desirable sampling framework. Approximately 99.5% of 
the eligible women received an invitation, and only 0.5% of the invitations were returned 
because of unknown residence. The results revealed a response rate of about 60% in the age 
groups of 30–34 years up to 55–59 years, with a response rate of 44.7% among those aged 
65–70. These, in general, are considered to be good response rates and are similar to what has 
been found in other population-based cohorts (47).  
Moreover, the external validity of the NOWAC study have been evaluated (47). Although the 
results revealed some differences in parity and education, no statistically significant 
difference was observed between respondents and nonrespondents regarding lifestyle factors. 
Privacy concerns and lack of time were reported among nonrespondents in a 
postquestionnaire survey. Lund et al. argued that the relationship between any of the reasons 
for not responding regarding specific lifestyle factors should be strong to cause selection bias. 
Several validation studies have shown that the distribution of exposure is independent of the 
response rate, which suggests high external validity (78, 79).  
Self-reported data on n-3 PUFA intake were utilized. Self-reported data are often necessitated 




subjective measurements, such as this one, are often considered inferior to objective ones, 
especially if they are not validated. Hence, longer follow-up durations are needed when 
assessing outcomes that take years to manifest and a large number of participants are needed 
to maintain statistical power. As a result, more objective measurements, such as blood 
samples and interviews, are not always feasible. In 2003, a validation study was performed, in 
which the internal validity of FFQs was evaluated (80). Four repeated 24 h recalls (telephone 
interviews with 238 women each season) were compared with FFQ data. It has been shown 
that the intake of fish and n-3 PUFAs is well correlated with serum phospholipid levels (76). 
Menopausal status and hormonal replacement therapy have also been validated against 
biomarkers of hormonal levels (81). Self-reported physical activity have also been reported as 
valid (82). There is some under-reporting of BMI among overweight and obese women, but 
otherwise valid (83). One of the drawbacks of self-reported data is over- and underestimation, 
including unlikely intake values. Outliers can potentially increase the variability and, 
therefore, reduce statistical power. Hence, the precision of the data in the present study was 
likely improved once exclusion criteria based on caloric intake and fish and fish products 
were applied (66).  
Overall, the methodology has been selected to reduce bias and maintain internal validity. The 
study population should also be reasonably representative of the general Norwegian female 
population between 30 and 70 years (47). The results of this study should not be generalized 
across different populations due to possible unknown effects of a variety of factors such as 
age, sex, ethnicity, lifestyle, biological predispositions, and climate.  
 
5.2.5 Model building 
Selection of confounders is driven by theory, on the basis of previous findings. Confounders 
are usually selected with regard to model contribution and correlation. Force entry was used 
because some research supports the initial selection of covariates. One disadvantage in the 
force entry method is that it heavily relies on good theoretical reasons for including the 
covariates. However, one of its strengths is that no hierarchical structure needs to be made, 
which is prone to random variation in the data. This method is considered to be superior and 




independently against the dependent variable (with a cut-off significance level of p ≤ 0.20) to 
avoid overfitting the model with predictors with little contribution. A correlation cut-off (r = 
0.73) was set to reduce standard errors and avoid untrustworthy b coefficients (66). Overall, 
parsimony heuristics were followed to keep the model simple and robust. Important 
covariates could, on the other hand, have been left out. However, information regarding 
cholesterol levels, stress, and family history was not obtainable. 
 
5.2.6 Residual confounders 
Generally, it is important to identify gene function variations only when they are consistently 
and systematically varying in the population (84). As briefly mentioned in the Introduction, 
there are several genetic predispositions to a disadvantageous lipid profile, which are the 
following hyperlipidemias: familial hypercholesterolemia, polygenic familial 
hypercholesterolemia, familial combined hyperlipidemia, and familial dysbetalipoproteinemia 
(5). Subjects with any of these conditions should have been excluded from the analysis, but 
no information regarding these conditions was obtainable. It is reasonable to assume that 
many of the subjects with these conditions were excluded because of hypertension, angina 
pectoralis, T2DM, stroke, and MI at baseline. Part of the population were also likely to have 
undiagnosed genetic conditions. A family history does not, however, equate to having the 
genetic condition itself or being susceptible to it (84). There are also studies suggesting that 
genetic variations could be responsible for different lipid responses (85-87). A study by 
Melarba et al. suggested that susceptibility to CVD could vary because polymorphisms of the 
FADS1 and FADS2 genes were associated with variations in EPA, LA, ALA, and AA serum 
levels. Most noteworthy was AA which is especially associated with inflammation (88). 
Genetic variations may contribute to inconsistent findings (87). Genetic variation may explain 
why there are positive findings in high-risk populations (41, 87). In contrast, study population 
homogeneity may cause an effect to be undetectable. There have also been reported gender 
differences in response to EPA and DHA. A 2008 RCT found that EPA and DHA 
(supplementing with 0.7 gram/day) had a greater effect on lowering triglycerides in males 
compared to females, which could make it harder to detect a protective effect against FMI 




may also contain different amounts of total n-3 PUFAs, as well as varying distributions of 
EPA and DHA, which could also confound the results. 
In the Seven Countries Study, it was concluded that not smoking and a healthy diet are 
prerequisites for low CHD rates (90). However, high intake of fish was not sufficient to lower 
the CHD rates in countries with high rates of smoking and diets with more saturated fat 
content and fewer antioxidants. As previously mentioned, western diets are rich in n-6 
PUFAs, which are associated with proinflammatory ratios (20). Western diets can, therefore, 
become prothrombotic and proaggregatory, which increases the blood viscosity and 
vasoconstriction (20). On this premise, high n-6 PUFA levels may prevent a potential 
prophylactic effect as LA and ALA compete for the same elongase and desaturase proteins. 
The Norwegian diet represents a western diet and may therefore be excessive in n-6 PUFA. 
On the other hand, some reports have concluded that the absolute n-3 PUFA intake is more 
important than the intake ratio (13). Perhaps there are other dietary, biological, and chemical 
factors affecting the bioavailability of n-3 PUFAs in the diet, thus ultimately affecting the 
blood levels of EPA and DHA (91).  
Cod liver oil and n-3 PUFA supplements contain vitamin D. The intake of these supplements 
usually varies from one season to another. Some people consume only n-3 PUFA 
supplements in the winter to maintain sufficient blood 25(OH)D levels. In a 2017 systematic 
review conducted by Huang et al., the authors found significantly lower levels of blood 
25(OH)D in patients with MI (92). Hence, they concluded that sufficient 25(OH)D levels may 
have a protective effect against MI. In the present study, some of the individuals who 
exclusively consume n-3 PUFA supplements in the winter may have been categorized as 
intermittent users. Hjartåker et al. found that 44% of women used cod liver oil or capsules and 
that 7% used other fish oil capsules in the NOWAC study (50). It was also observed that the 
proportion of those using cod liver oil increased with age. However, no age trends were found 
for those who have reported using other fish oil products. All models are age-standardized in 
the present study, but vitamin D status could potentially be an important confounder 
unadjusted for. 
Generally, environmental contaminants, such as persistent organic pollutants, and heavy 




n-3 PUFA (93). However, in a Norwegian project commissioned by the Norwegian Food 
Safety Authority and performed at the Institute of Marine Research, the researchers analyzed 
seven fish oils, one mixed fish and plant oil, one seal oil, and one microalgal oil for dioxin-
like polychlorinated biphenyls  (PCBs), dioxins, non-dioxin-like PCBs, polybrominated flame 
retardants, and the elements arsenic, cadmium, mercury, lead, and selenium (94). Large 
variations were observed in the levels of organic contaminants between different oils. 
However, none of the oils exceeded the maximum levels set by the European Union. 
Some studies have also pointed out the possible negative effects of consuming oxidized 
lipids, although to our knowledge no human interventional studies on this issue have yet been 
conducted (95, 96). Several animal studies have shown that oxidized lipids may cause 
inflammation and advanced atherosclerosis. In general, n-3 PUFAs are easily oxidized by 
light, air, and temperature over time because of the unstable nature of double bonds. During 
this process, different primary oxidation products (peroxides) form, which are unstable and 
prone to further degradation into secondary oxidation products. Further degradation may lead 
to potential harmful compounds. Ingesting over-the-counter n-3 PUFA supplements involves 
some risk of exposure to oxidized oils. In an RCT, Ottestad et al. found that a variety of 
markers of lipid peroxidation, oxidative stress, and inflammation were not significantly 
affected in healthy individuals who consume 8 g of highly oxidized fish oil daily (for three 
and seven weeks) (97). However, little is currently known regarding the oxidation status in 
other marine n-3 PUFA products and the extent to which this would have a negative effect 
(95, 97). On the other hand, antioxidants are often added to reduce oxidation; however, they 








6 Conclusions and recommendations for future research 
In this prospective cohort study, the aim was to investigate whether a higher intake frequency 
of n-3 PUFA supplements is useful as a primary prevention method against FMI among 
women in the NOWAC study. The results are correlational, meaning that it does not show any 
causal relationships, but can nevertheless contribute to future research. 
The results are in line with some of the previous findings (34-40, 42-44, 46). Researchers 
have suggested that an effect may be hard to detect due to effective treatment (34, 43, 44). 
Most participants who were likely receiving treatment related to CVD were excluded from the 
present study. Similar results were found by Manson et al. in an RCT, where there was a 
lower incidence of CVD among those who supplemented with n-3 PUFAs and had low fish 
consumption (44). However, no associations were found once the models were adjusted for 
confounding factors. 
Future research should assess if there is a higher cut-off dosage where n-3 PUFA supplements 
have a prophylactic effect against CVD within different fish intake groups in healthy 
populations. 
In summary, more frequent intakes of n-3 PUFA supplements are not associated with a lower 













1. Raymond JL, Couch SC. Medical Nutrition Therapy for Cardiovascular Disease. In: 
Mahan LK, Escott-Stump S, Raymond JL, editors. Krause's Food and the Nutrition Care 
Process 13th ed: ELSEVIER; 2012. p. 742-81. 
2. Global, regional, and national life expectancy, all-cause mortality, and cause-specific 
mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of 
Disease Study 2015. Lancet. 2016;388(10053):1459-544. doi:10.1016/s0140-6736(16)31012-
1 
3. Knudsen A, Tollånes M, Haaland Ø, Kinge J, Skirbekk V, Vollset S. Sykdomsbyrde i 
Norge 2015. Resultater fra Global Burden of Diseases, Injuries, and Risk Factors Study 2015 
(GBD 2015) [Burden of disease in Norway 2015. Results from Global Burden of Diseases, 
Injuries, and Risk Factors Study 2015 (GBD 2015)]. Retrieved. 2017;8:2019. Norwegian.  
4. Khanji MY, van Waardhuizen CN, Bicalho VVS, Ferket BS, Hunink MGM, Petersen 
SE. Lifestyle advice and interventions for cardiovascular risk reduction: A systematic review 
of guidelines. Int J Cardiol. 2018;263:142-51. doi:10.1016/j.ijcard.2018.02.094 
5. Govatsmark RES, Halle KK, Berge VB, Sneeggen S, Bønaa KH. The Norwegian 
Myocardial Infarction Register, Annual report 2019. https://stolav.no/norsk-
hjerteinfarktregister/; 2020. 
6. Mendis S, Thygesen K, Kuulasmaa K, Giampaoli S, Mähönen M, Ngu Blackett K, et 
al. World Health Organization definition of myocardial infarction: 2008–09 revision. 
International Journal of Epidemiology. 2010;40(1):139-46. doi:10.1093/ije/dyq165 
7. Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and 
rupture. Circulation research. 2014;114(12):1852-66.  
8. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of 
potentially modifiable risk factors associated with myocardial infarction in 52 countries (the 
INTERHEART study): case-control study. Lancet. 2004;364(9438):937-52. 
doi:10.1016/s0140-6736(04)17018-9 
9. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. 
Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 





10. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk 
factor. The American Journal of Cardiology. 2000;86(9):943-9. doi:10.1016/S0002-
9149(00)01127-9 
11. Hokanson JE, Austin MA. Plasma Triglyceride Level is a Risk Factor for 
Cardiovascular Disease Independent of High-Density Lipoprotein Cholesterol Level: A 
Metaanalysis of Population-Based Prospective Studies. Journal of Cardiovascular Risk. 
1996;3(2):213-9. doi:10.1177/174182679600300214 
12. Jones PJ, Rideout T. Lipids, sterols, and their metabolites. In: Ross AC, Caballero B, 
Cousins RJ, Tucker KL, Ziegler TR, editors. Modern nutrition in health and disease. 11 ed: 
Lippincott Williams & Wilkins; 2006. p. 65-87. 
13. Nordic Nutrition Recommendations 2012: Integrating nutrition and physical activity. 
5th ed: Nordic Council of Ministers; 2014. 
14. Gallagher ML. Intake: The Nutrients and Their Metabolism. In: Mahan LK, Escott-
Stump S, Raymond JL, editors. Krause's Food and the Nutrition Care Process 13th ed: 
ELSEVIER; 2012. p. 33-128. 
15. Surette ME. The science behind dietary omega-3 fatty acids. CMAJ. 2008;178(2):177-
80. doi:10.1503/cmaj.071356 
16. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on 
risk factors, molecular pathways, and clinical events. Journal of the American College of 
Cardiology. 2011;58(20):2047-67.  
17. Gómez FE, Kaufer-Horwitz M. Medical Nutrition Therapy for Rheumatic Disease. In: 
Mahan LK, Escott-Stump S, Raymond JL, editors. Krause's Food and the Nutrition Care 
Process 13th ed: ELSEVIER; 2012. p. 901-22. 
18. Nakamura MT, Nara TY. Essential fatty acid synthesis and its regulation in mammals. 
Prostaglandins, Leukotrienes and Essential Fatty Acids. 2003;68(2):145-50. 
doi:10.1016/S0952-3278(02)00264-8 
19. Wertz P. Essential fatty acids and dietary stress. Toxicology and industrial health. 
2009;25(4-5):279-83.  
20. Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. 
Biomedicine & pharmacotherapy. 2002;56(8):365-79.  
21. Mori T, Beilin L. Omega-3 fatty acids and inflammation. Current Atherosclerosis 




22. Eritsland J. Safety considerations of polyunsaturated fatty acids. Am J Clin Nutr. 
2000;71(1 Suppl):197s-201s. doi:10.1093/ajcn/71.1.197S 
23. Andersen S, HM M. Anbefalinger om kosthold, ernæring og fysisk aktivitet 
[Recommendations for diets, nutrition and physical activity]. Report IS. 2014;2170. 
Norwegian.  
24. Meyer H, Brunvand L, Brustad M, Holvik K, Johansson L, Paulsen J. Tiltak for å sikre 
en god vitamin D-status i befolkningen [Proposals to secure a good vitamin D-status in the 
population], Rapport IS-1408. Norwegian Nutrition Council; 2006. 
25. Brustad M, Braaten T, Lund E. Predictors for cod-liver oil supplement use--the 
Norwegian Women and Cancer Study. European journal of clinical nutrition. 2004;58(1):128-
36.  
26. Bang HO, Dyerberg J, Nielsen AB. Plasma lipid and lipoprotein pattern in 
Greenlandic West-coast Eskimos. Lancet. 1971;1(7710):1143-5. doi:10.1016/s0140-
6736(71)91658-8 
27. Bang HO, Dyerberg J, Sinclair HM. The composition of the Eskimo food in north 
western Greenland. The American Journal of Clinical Nutrition. 1980;33(12):2657-61. 
doi:10.1093/ajcn/33.12.2657 
28. Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between 
fish consumption and 20-year mortality from coronary heart disease. N Engl J Med. 
1985;312(19):1205-9. doi:10.1056/nejm198505093121901 
29. Zheng J, Huang T, Yu Y, Hu X, Yang B, Li D. Fish consumption and CHD mortality: 
an updated meta-analysis of seventeen cohort studies. Public Health Nutr. 2012;15(4):725-37. 
doi:10.1017/s1368980011002254 
30. Hu FB, Bronner L, Willett WC, Stampfer MJ, Rexrode KM, Albert CM, et al. Fish 
and Omega-3 Fatty Acid Intake and Risk of Coronary Heart Disease in Women. JAMA. 
2002;287(14):1815-21. doi:10.1001/jama.287.14.1815 
31. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. 
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients 





32. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after 
myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio 
della Sopravvivenza nell'Infarto miocardico. Lancet. 1999;354(9177):447-55.  
33. Yli-Jama P, Meyer HE, Ringstad J, Pedersen JI. Serum free fatty acid pattern and risk 
of myocardial infarction: a case-control study. J Intern Med. 2002;251(1):19-28. 
doi:10.1046/j.1365-2796.2002.00922.x 
34. Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H, et al. OMEGA, a 
randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids 
on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 
2010;122(21):2152-9. doi:10.1161/circulationaha.110.948562 
35. Kromhout D, Giltay EJ, Geleijnse JM. n–3 Fatty Acids and Cardiovascular Events 
after Myocardial Infarction. New England Journal of Medicine. 2010;363(21):2015-26. 
doi:10.1056/NEJMoa1003603 
36. Bosch J, Gerstein HC, Dagenais GR, Diaz R, Dyal L, Jung H, et al. n-3 fatty acids and 
cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309-18. 
doi:10.1056/NEJMoa1203859 
37. Lemaitre RN, King IB, Mozaffarian D, Kuller LH, Tracy RP, Siscovick DS. n-3 
Polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal myocardial infarction in 
older adults: the Cardiovascular Health Study. Am J Clin Nutr. 2003;77(2):319-25. 
doi:10.1093/ajcn/77.2.319 
38. n–3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors. New England 
Journal of Medicine. 2013;368(19):1800-8. doi:10.1056/NEJMoa1205409 
39. Amiano P, Machon M, Dorronsoro M, Chirlaque MD, Barricarte A, Sanchez MJ, et al. 
Intake of total omega-3 fatty acids, eicosapentaenoic acid and docosahexaenoic acid and risk 
of coronary heart disease in the Spanish EPIC cohort study. Nutr Metab Cardiovasc Dis. 
2014;24(3):321-7. doi:10.1016/j.numecd.2013.08.011 
40. Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, et al. 
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. 
Cochrane Database Syst Rev. 2018;11:Cd003177. doi:10.1002/14651858.CD003177.pub4 
41. Alexander DD, Miller PE, Van Elswyk ME, Kuratko CN, Bylsma LC. A Meta-
Analysis of Randomized Controlled Trials and Prospective Cohort Studies of 




Heart Disease Risk. Mayo Clinic Proceedings.92(1):15-29. 
doi:10.1016/j.mayocp.2016.10.018 
42. Roncaglioni MC, Tombesi M, Avanzini F, Barlera S, Caimi V, Longoni P, et al. n-3 
fatty acids in patients with multiple cardiovascular risk factors. The New England journal of 
medicine. 2013;368(19):1800-8. doi:10.1056/nejmoa1205409 
43. Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, et al. 
Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: 
Meta-analysis of 10 Trials Involving 77917 Individuals. JAMA Cardiol. 2018;3(3):225-34. 
doi:10.1001/jamacardio.2017.5205 
44. Manson JE, Cook NR, Lee I-M, Christen W, Bassuk SS, Mora S, et al. Marine n−3 
Fatty Acids and Prevention of Cardiovascular Disease and Cancer. New England Journal of 
Medicine. 2018;380(1):23-32. doi:10.1056/NEJMoa1811403 
45. Siscovick DS, Barringer TA, Fretts AM, Wu JH, Lichtenstein AH, Costello RB, et al. 
Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical 
cardiovascular disease: a science advisory from the American Heart Association. Circulation. 
2017;135(15):e867-e84.  
46. Kalstad AA, Myhre PL, Laake K, Tveit SH, Schmidt EB, Smith P, et al. Effects of n-3 
Fatty Acid Supplements in Elderly Patients after Myocardial Infarction: A Randomized 
Controlled Trial. Circulation.0(0). doi:doi:10.1161/CIRCULATIONAHA.120.052209 
47. Lund E, Kumle M, Braaten T, Hjartaker A, Bakken K, Eggen E, et al. External 
validity in a population-based national prospective study--the Norwegian Women and Cancer 
Study (NOWAC). Cancer Causes Control. 2003;14(10):1001-8.  
48. Lund E, Dumeaux V, Braaten T, Hjartåker A, Engeset D, Skeie G, et al. Cohort 
Profile: The Norwegian Women and Cancer Study—NOWAC—Kvinner og kreft. 
International Journal of Epidemiology. 2007;37(1):36-41. doi:10.1093/ije/dym137 
49. Dalane J, Bergvatn T, Kielland E, Carlsen M. Mål, vekt og porsjonsstørrelser for 
matvarer [Weights, measures and portion sizes for foods]. Oslo, Norway: The Norwegian 
Food Safety Authority (Mattilsynet), University of Oslo (Universitetet i Oslo), The 
Norwegian Directorate of Health (Helsedirektoratet). 2015.  
50. Hjartåker A, Lund E. Relationship between dietary habits, age, lifestyle, and socio-
economic status among adult Norwegian women. The Norwegian Women and Cancer Study. 




51. Bowers D. Measuring survival.  Medical statistics from scratch: an introduction for 
health professionals. 3rd ed: John Wiley & Sons; 2019. p. 311-24. 
52. IBM®. IBM SPSS advanced statistics 20. IBM Corporation. 2011.  
53. World Health O. ICD-10 : international statistical classification of diseases and related 
health problems : tenth revision. 2nd ed ed. Geneva: World Health Organization; 2004. 
54. Kravdal Ø, Tverdal A, Grundy E. The association between parity, CVD mortality and 
CVD risk factors among Norwegian women and men. European Journal of Public Health. 
2020.  
55. Zhu J, Su X, Li G, Chen J, Tang B, Yang Y. The incidence of acute myocardial 
infarction in relation to overweight and obesity: a meta-analysis. Archives of medical science: 
AMS. 2014;10(5):855.  
56. Joseph P, Leong D, McKee M, Anand SS, Schwalm J-D, Teo K, et al. Reducing the 
global burden of cardiovascular disease, part 1: the epidemiology and risk factors. Circulation 
research. 2017;121(6):677-94.  
57. Barger SD, Cribbet MR, Muldoon MF. Participant‐Reported health status predicts 
cardiovascular and All‐Cause mortality independent of established and nontraditional 
biomarkers: evidence from a representative US sample. Journal of the American Heart 
Association. 2016;5(9):e003741.  
58. Carter AR, Gill D, Davies NM, Taylor AE, Tillmann T, Vaucher J, et al. 
Understanding the consequences of education inequality on cardiovascular disease: mendelian 
randomisation study. bmj. 2019;365.  
59. Winkleby MA, Fortmann SP, Rockhill B. Trends in cardiovascular disease risk factors 
by educational level: the Stanford Five-City Project. Preventive medicine. 1992;21(5):592-
601.  
60. Atsma F, Bartelink M-LE, Grobbee DE, van der Schouw YT. Postmenopausal status 
and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. 
Menopause. 2006;13(2):265-79.  
61. Peters SA, Yang L, Guo Y, Chen Y, Bian Z, Du J, et al. Breastfeeding and the risk of 
maternal cardiovascular disease: a prospective study of 300 000 Chinese women. Journal of 




62. Jayedi A, Shab-Bidar S, Eimeri S, Djafarian K. Fish consumption and risk of all-cause 
and cardiovascular mortality: a dose–response meta-analysis of prospective observational 
studies. Public Health Nutrition. 2018;21(7):1297-306.  
63. Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Miller NH, Hubbard VS, et al. 2013 
AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the 
American College of Cardiology/American Heart Association Task Force on Practice 
Guidelines. Journal of the American College of Cardiology. 2014;63(25 Part B):2960-84.  
64. Hooper L, Martin N, Abdelhamid A, Smith GD. Reduction in saturated fat intake for 
cardiovascular disease. Cochrane database of systematic reviews. 2015(6).  
65. Hooper L, Summerbell CD, Higgins JP, Thompson RL, Capps NE, Smith GD, et al. 
Dietary fat intake and prevention of cardiovascular disease: systematic review. Bmj. 
2001;322(7289):757-63.  
66. Field A. The Linear Regression (Regression).  Discovering Statistics Using IBM SPSS 
Statistics. 5th ed: Sage; 2018. p. 369-436. 
67. Wood DM, Mould MG, Ong SBY, Baker EH. “Pack year” smoking histories: what 
about patients who use loose tobacco? Tobacco Control. 2005;14(2):141-2. 
doi:10.1136/tc.2004.009977 
68. Sterne JAC, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple 
imputation for missing data in epidemiological and clinical research: potential and pitfalls. 
BMJ. 2009;338:b2393. doi:10.1136/bmj.b2393 
69. Thabane L, Mbuagbaw L, Zhang S, Samaan Z, Marcucci M, Ye C, et al. A tutorial on 
sensitivity analyses in clinical trials: the what, why, when and how. BMC Medical Research 
Methodology. 2013;13(1):92. doi:10.1186/1471-2288-13-92 
70. VanderWeele TJ, Knol MJ. A Tutorial on Interaction. Epidemiologic Methods. 
2014;3(1):33-72. doi:10.1515/em-2013-0005 
71. Sutcliffe P, Connock M, Gurung T, Freeman K, Johnson S, Kandala N-B, et al. 
Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a 
systematic review and overview of reviews. Health Technology Assessment (Winchester, 
England). 2013;17(43):1.  
72. Hybiak J, Broniarek I, Kiryczyński G, Los LD, Rosik J, Machaj F, et al. Aspirin and 





73. Dale O, Borchgrevink PC, Fredheim OMS, Mahic M, Romundstad P, Skurtveit S. 
Prevalence of use of non-prescription analgesics in the Norwegian HUNT3 population: 
Impact of gender, age, exercise and prescription of opioids. BMC public health. 
2015;15(1):461.  
74. Jortveit J, Govatsmark RES, Digre TA, Risøe C, Hole T, Mannsverk J, et al. 
Myocardial infarction in Norway in 2013. Tidsskrift for Den norske legeforening. 
2014;19(134):1841-6.  
75. Bhopal RS. Epidemiological study designs and principles of data analysis: A 
conceptually integrated suite of methods and techniques.  Concepts of epidemiology: 
integrating the ideas, theories, principles, and methods of epidemiology. 3rd ed: Oxford 
University Press; 2016. p. 335. 
76. Hjartåker A, Lund E, Bjerve K. Serum phospholipid fatty acid composition and 
habitual intake of marine foods registered by a semi-quantitative food frequency 
questionnaire. European journal of clinical nutrition. 1997;51(11):736-42.  
77. Bonita R, Beaglehole R, Kjellström T. Basic epidemiology. 2nd ed: World Health 
Organization; 2006. 
78. Lund E, Gram I. The impact of design on response rates and exposure estimates from 
postal questionnaires. A population based randomized trial of 5.000 Norwegian women aged 
35–49 years. Scand J Soc Med. 1998;26:154-60.  
79. Lund E, Gram IT. Response rate according to title and length of questionnaire. 
Scandinavian journal of social medicine. 1998;26(2):154-60.  
80. Hjartåker A, Andersen LF, Lund E. Comparison of diet measures from a food-
frequency questionnaire with measures from repeated 24-hour dietary recalls. The Norwegian 
Women and Cancer Study. Public health nutrition. 2007;10(10):1094-103.  
81. Waaseth M, Bakken K, Dumeaux V, Olsen KS, Rylander C, Figenschau Y, et al. 
Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian 
Women and Cancer postgenome cohort - a cross-sectional analysis. BMC Womens Health. 
2008;8:1. doi:10.1186/1472-6874-8-1 
82. Borch KB, Ekelund U, Brage S, Lund E. Criterion validity of a 10-category scale for 





83. Skeie G, Mode N, Henningsen M, Borch KB. Validity of self-reported body mass 
index among middle-aged participants in the Norwegian Women and Cancer study. Clin 
Epidemiol. 2015;7:313-23. doi:10.2147/clep.S83839 
84. Bhopal RS. Variation in disease by time, place, and person: Background and a 
framework for analysis of genetic and environmental effects.  Concepts of epidemiology: 
integrating the ideas, theories, principles, and methods of epidemiology. 3rd ed: Oxford 
University Press; 2016. p. 54-64. 
85. Masson LF, McNeill G, Avenell A. Genetic variation and the lipid response to dietary 
intervention: a systematic review. The American Journal of Clinical Nutrition. 
2003;77(5):1098-111. doi:10.1093/ajcn/77.5.1098 
86. Rudkowska I, Guénard F, Julien P, Couture P, Lemieux S, Barbier O, et al. Genome-
wide association study of the plasma triglyceride response to an n-3 polyunsaturated fatty acid 
supplementation. J Lipid Res. 2014;55(7):1245-53. doi:10.1194/jlr.M045898 
87. Cormier H, Rudkowska I, Paradis A-M, Thifault E, Garneau V, Lemieux S, et al. 
Association between Polymorphisms in the Fatty Acid Desaturase Gene Cluster and the 
Plasma Triacylglycerol Response to an n-3 PUFA Supplementation. Nutrients. 
2012;4(8):1026-41.  
88. Malerba G, Schaeffer L, Xumerle L, Klopp N, Trabetti E, Biscuola M, et al. SNPs of 
the FADS Gene Cluster are Associated with Polyunsaturated Fatty Acids in a Cohort of 
Patients with Cardiovascular Disease. Lipids. 2008;43(4):289-99. doi:10.1007/s11745-008-
3158-5 
89. Caslake MJ, Miles EA, Kofler BM, Lietz G, Curtis P, Armah CK, et al. Effect of sex 
and genotype on cardiovascular biomarker response to fish oils: the FINGEN Study. The 
American Journal of Clinical Nutrition. 2008;88(3):618-29. doi:10.1093/ajcn/88.3.618 
90. Kromhout D, Bloemberg BP, Feskens EJ, Hertog MG, Menotti A, Blackburn H. 
Alcohol, fish, fibre and antioxidant vitamins intake do not explain population differences in 
coronary heart disease mortality. International journal of epidemiology. 1996;25(4):753-9.  
91. Cholewski M, Tomczykowa M, Tomczyk M. A Comprehensive Review of Chemistry, 





92. Huang J, Wang Z, Hu Z, Jiang W, Li B. Association between blood vitamin D and 
myocardial infarction: A meta-analysis including observational studies. Clinica Chimica Acta. 
2017;471:270-5.  
93. Turunen AW, Jula A, Suominen AL, Männistö S, Marniemi J, Kiviranta H, et al. Fish 
consumption, omega-3 fatty acids, and environmental contaminants in relation to low-grade 
inflammation and early atherosclerosis. Environmental Research. 2013;120:43-54. 
doi:10.1016/j.envres.2012.09.007 
94. Nilsen BM, Sanden M. Miljøgifter i fisk og fiskevarer 2017–Dioksiner og 
dioksinlignende PCB, ikke-dioksinlignende PCB, polybromerte flammehemmere og 
tungmetaller i marine oljer til humant konsum [Envirmonmental toxins in fish and fish 
products 2017-Dioxins and dioxin-like PCB, non-dioxin-like PCB, polybrominated fire 
retardants and heavy metals in marine oils for human consumption]. Rapport fra 
havforskningen. 2018. Norwegian.  
95. Lise Halvorsen B, Blomhoff R. Determination of lipid oxidation products in vegetable 
oils and marine omega-3 supplements. Food & nutrition research. 2011;55(1):5792.  
96. Albert BB, Cameron-Smith D, Hofman PL, Cutfield WS. Oxidation of Marine 
Omega-3 Supplements and Human Health. BioMed Research International. 
2013;2013:464921. doi:10.1155/2013/464921 
97. Ottestad I, Vogt G, Retterstøl K, Myhrstad MC, Haugen J-E, Nilsson A, et al. 
Oxidised fish oil does not influence established markers of oxidative stress in healthy human 










The literature search was conducted 22. October 2019 with 104 items found. All myocardial 
infarction mesh terms were combined with omega-3 or fish oils ("Myocardial 
Infarction"[Mesh]) AND ("Fatty Acids, omega-3"[Mesh] OR "Fish Oils"[Mesh]). Filters: full 
text, published in the last 10 years, humans and English. There were 27 randomized 
controlled trials among these. 
Medline 
The literature search was conducted in Medline database 24. October 2019 with 82 items 
found. All myocardial infarction mesh terms were combined with all fish oil terms. Booleans 
for detecting myocardial infarction in title (ti), abstract (ab) and keywords (kw) were used. 
The ADJ3 operator was used to find myocardial infarction in any order with two words or 
fewer between them. The following search was done: (Myocardial adj3 infarction).ti,ab,kw 
AND exp Fish Oils/. Filters: published between 2009 and 2019 (past 10 years), humans, all 
journals and all publication types. 
Cochrane library 
The literature search was conducted in Cochrane Library 1. November 2019 with 29 items 
found. All myocardial infarction mesh terms were combined with all fish oil terms. Line one: 
MeSH descriptor: [Fish Oils] explode all trees, line two: MeSH descriptor: [Myocardial 
Infarction] explode all trees, line tree: #1 AND #2, limits: Cochrane Reviews, Trials and 
Between Jan. 2009 and Oct. 2019 (10 years). 
Google Scholar 
A literature search was done in Google Scholar 1. November 2019 with 34 items found. The 
following combination was used: allintitle: "myocardial infarction" AND "fish oil" OR 
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PubMed ("Myocardial Infarction"[Mesh]) AND 
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Fish intake percentiles 
 
  Fatty fish Fish and fish products Lean fish 
N Valid 101316 101316 101316 
Missing 0 0 0 
Mean 15.96 97.59 30.51 
Median 11.44 87.15 23.66 
Std. Deviation 19.260 60.041 29.664 
Variance 370.965 3604.930 879.944 
Range 495 893 245 
Minimum 0 0 0 
Maximum 495 893 245 
Percentiles 5 0.00 22.39 0.00 
10 0.00 34.15 0.00 
15 0.00 42.74 4.13 
20 1.60 49.90 6.27 
25 4.12 56.38 9.69 
30 4.95 62.46 12.54 
35 6.60 68.36 15.77 
40 7.84 74.51 16.53 
45 9.65 80.73 20.38 
50 11.44 87.15 23.66 
55 12.87 93.77 27.17 
60 14.82 100.76 28.26 
65 16.60 108.43 32.21 
70 19.31 116.76 39.43 
75 21.86 126.56 40.76 
80 25.03 138.09 50.16 
85 28.68 152.82 54.34 
90 35.44 172.90 67.93 
95 48.36 206.55 81.51 
96 53.54 217.58 95.10 
97 58.03 232.63 108.68 
98 67.93 254.10 108.68 
99 85.80 292.29 135.85 
99.1 88.11 298.43 138.04 
99.2 91.21 305.33 145.92 
99.3 96.41 312.90 163.02 
99.4 102.70 323.47 163.02 
99.5 109.96 333.92 163.02 
99.6 115.82 350.43 163.02 
99.7 127.40 372.34 163.02 
99.8 147.46 402.75 176.61 











Correlation (Pearson r) matrix: Covariates. 
 
    1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
1 Age                 
2 BMI 0.08                
3 Smoking -0.08 -0.06               
4 
Physical 




health -0.09 -0.11 -0.12 0.24             
6 Education -0.22 -0.09 -0.15 0.05 0.17            
7 Menopause 0.54 0.06 0 -0.01 -0.06 -0.13           
8 Breastfed -0.04 -0.01 -0.02 0.03 0.03 0.01 -0.03          
9 Parity 0.13 0.06 -0.06 0.01 -0.02 -0.15 0.06 0.46         
10 
Fatty fish 
intake 0.1 0 0.01 0.06 0.03 0.07 0.06 0 -0.03        
11 Fish intake 0.12 0.03 0.04 0.06 -0.03 -0.06 0.07 0.02 0.05 0.54       
12 
Lean fish 
intake 0.15 0.04 0.02 0.01 -0.06 -0.16 0.08 0.02 0.1 0.17 0.73      
13 
Total fatty 
acids -0.09 -0.09 0.05 0.08 0.02 0.05 -0.02 0.05 0.03 0.2 0.31 0.12     
14 
Saturated 
fatty acids -0.09 -0.09 0.04 0.06 0.01 0.04 -0.03 0.04 0.04 0.1 0.22 0.09 0.95    
15 Fruit intake 0.08 0.02 -0.15 0.12 0.08 0.11 0.07 0.01 -0.02 0.14 0.12 0.02 0.07 0.04   
16 
Vegetable 
intake -0.02 0.01 -0.02 0.13 0.05 0.14 0.02 0.02 -0.03 0.23 0.26 0.08 0.17 0.1 0.32   
 
 
 
 
 
 
